01349.HK
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.51
+0.20%Year over year
Reported trailing growth
- Revenue
- -3.8%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +491.2%
- Operating cash flow
- +819.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -12.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +12.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026